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Bile acid has been well known to serve as a hormone in regulating transcriptional activity of Farnesoid X receptor (FXR), 
an endogenous bile acid nuclear receptor. Moreover, bile acid regulates diverse biological processes, including cholesterol/bile 
acid metabolism, glucose/lipid metabolism and energy expenditure. Alteration of bile acid metabolism has been revealed 
in type II diabetic (T2D) patients. FXR-mediated bile acid signaling has been reported to play key roles in improving metabolic 
parameters in vertical sleeve gastrectomy surgery, implying that FXR is an essential modulator in the metabolic homeostasis. 
Using a genetic mouse model, intestinal specific FXR-null mice have been reported to be resistant to diet-induced obesity 
and insulin resistance. Moreover, intestinal specific FXR agonism using gut-specific FXR synthetic agonist has been shown 
to enhance thermogenesis in brown adipose tissue and browning in white adipose tissue to increase energy expenditure, 
leading to reduced body weight gain and improved insulin resistance. Altogether, FXR is a potent therapeutic target for 
the treatment of metabolic diseases. (J Lipid Atheroscler 2017 June;6(1):1-7)
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INTRODUCTION
Bile acids are converted from cholesterol in the liver 
by numerous cytochrome P450 enzymes, including 
cholesterol-7α-hydroxylase (CYP7A1), steroid 7α-hydroxy-
lase (CYP27A1) and sterol-27-hydroxylase (CYP27A1).1 
Bile acids have been well known to serve as digestive 
juice to emulsify lipid and promote lipid absorption in 
the intestinal tract. After endogenous bile acid nuclear 
receptor Farnesoid X Receptor (FXR) has been reported,2,3 
bile acids are now widely accepted as metabolic regulator 
to control whole body homeostasis, such as glucose/lipid 
metabolism and energy expenditure. Thus, the discovery 
of endogenous bile acid nuclear receptor FXR proposes 
new perspectives to understand molecular mechanisms 
and physiological roles of bile acids and their receptors 
in various tissues to maintain whole body homeostasis. 
1. FXR: Nuclear bile acid receptor
FXR belongs to nuclear receptor superfamily that 
contains both DNA and ligand binding domains.4-6 With 
absence of ligand, nuclear receptors generally bind to their 
responsive elements with corepressors, including Silencing 
Mediators of Retinoic acid and Thyroid hormone receptor 
(SMRT) and histone deacetylases (HDACs) and suppresses 
their target gene expressions. Upon binding with their 
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Fig. 1. Structure and transcriptional regulation of nuclear receptor. NR; nuclear receptor.
ligands, nuclear receptors interact with numerous coactiv-
ators and induce their target gene expressions (Fig. 1). 
FXR heterodimerizes with retinoid X receptor (RXR) and 
binds to the FXR response element which is localized in 
the promoter region of FXR target genes.4-7 FXR is 
expressed in various tissues, including liver, adrenal glands, 
intestine, adipose tissue, endothelial wall, pancreas and 
kidney.6 
Bile acids play as endogenous FXR ligands with high 
affinity. Both free and conjugated bile acids are able to 
activate FXR. A well-known hydrophobic bile acid, cheno-
deoxycholic acid (CDCA) is the most efficacious ligand 
of FXR (EC50=10μM).2,8,9 Generally, the order of potency 
of bile acids is CDCA>lithocholic acid (LCA)=deoxycholic 
acid (DCA)>cholic acid (CA).9 Interestingly, hydrophilic 
bile acids, including ursodeoxycholic acid (UDCA) and 
muricholic acid (MCA) were not able to activate FXR.10 
A synthetic bile acid derivative, 6α-ethylchenodeoxycholic 
acid (6-ECDCA) has been developed and reported with 
a higher affinity with FXR than the natural bile acids.9 
6-ECDCA recently has been renamed as obeticholic acid, 
which has recently been approved as a therapeutic reagent 
for primary biliary cirrhosis (PBC) by Food and Drug 
Administration,11,12 suggesting that FXR is a therapeutic 
potential target for other metabolic diseases.
2. Regulation of entero-hepatic bile acid circulation
Bile acids are generally conjugated to taurine or glycine 
upon synthesis. After conjugation, bile acids are secreted 
into the bile canaliculi. Upon food intake, feeding signal 
stimulates bile acid secretion into small intestine. Mostly, 
95% of secreted bile acids are recycled by entero-hepatic 
circulation; The remaining 5% of the bile acids excluded 
in each entero-hepatic circulation. Therefore, the con-
version of bile acid from cholesterol compensates an 
equivalent amount of bile acids to maintain a constant 
bile acid pool size in the system. 
The recycle of 95% of bile acids via entero-hepatic 
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Fig. 2. Regulation of cholesterol/bile acid metabolism by FXR. CYP7A1; Cholesterol-7α-hydroxylase,
SHP; Small heterodimer partner, RXR; Retinoid X receptor, FXR; Farnesoid X receptor.
circulation requires the apical sodium-dependent bile salt 
transporter (ASBT).6,8,13,14 After transporting bile acids 
inside enterocytes by ASBT, bile acids are bound by the 
intestinal bile acid-binding protein (IBABP) which is critical 
for entero-hepatic circulation of bile acids. Besides ASBT, 
organic solute transporter alpha and beta (OSTα and β) 
transport bile acids to the blood vessel, the portal vein.14 
Thus, elevated level of bile acids in the intestine induces 
expression of genes in bile acid transporters to transport 
bile acids from the intestine to the liver. 
3. Physiological roles of FXR in cholesterol/bile acid 
metabolism
As properties of bile acids are detergent to emulsify 
lipid substance, accumulation of bile acids in the 
hepatocytes leads to hepatotoxicity. Bile acid synthesis 
occurs in the hepatocytes and comprises two pathways: 
there are two key enzymes, such as CYP7A1 and CYP27A1, 
respectively.1,5 Upon FXR activation by bile acids, FXR 
induces gene expression of small heterodimer partner 
(SHP), which suppresses gene expression of CYP7A1 to 
reduce the rate of hepatic bile acid synthesis via negative 
feedback (Fig. 2).5,7,15,16
Besides CYP7A1 suppression by SHP, bile acid signaling 
from intestinal is able to regulate hepatic bile acid 
synthesis.17 Secretion of bile acids into small intestine 
activates transcriptional activity of FXR in the intestine, 
leading to induction of fibroblast growth factor 15/19 
(FGF15/19) gene expression as well as bile acid transporter 
in the small intestine. The elevated FGF15/19 proteins go 
back to the liver via portal vein and bind to the fibroblast 
growth factor receptor 4 (FGFR4) of hepatocytes. Upon 
activation of FGFR4, c-Jun NH(2)-terminal kinase (JNK) 
signaling pathway in turn suppresses CYP7A1 gene 
expression to reduce bile acid synthesis in the liver (Fig. 
3).18-21 
4. Physiological roles of FXR in the hepatic 
glucose/lipid metabolism
Generation of FXR-null mice has shown impaired 
glucose tolerance and insulin resistance, suggesting that 
FXR plays a pivotal role in glucose homeostasis. FXR is 
able to control gene expression of phosphoenolpyruvate 
carboxykinase (PEPCK), which is located in the liver to 
catalyze a crucial step of hepatic gluconeogenesis.6,22,23 
Besides PEPCK, FXR activation represses gene expression 
of glucose-6-phosphatase (G6pc), which catalyzes the 
hydrolysis of glucose-6-phosphate to glucose. In addition, 
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Fig. 3. Regulation of bile acid synthesis by FXR in the intestine. FXR; Farnesoid X receptor, RXR; Retinoid
X receptor, FGFR4; Fibroblast Growth Factor Receptor 4, CYP7A1; Cholesterol-7α-hydroxylase.
FXR activation also increases glycogen levels in the liver 
as via enhancing downstream insulin receptor signaling.6,23
FXR-null mice studies further revealed the physiological 
roles of FXR to regulate lipid metabolism.24 Compared 
with littermate control, FXR-null mice exhibited elevated 
levels of plasma triglycerides and cholesterol.6,24 In 
addition, FXR-null mice also showed higher levels of 
lipoprotein (HDL) cholesterol in plasma than littermate 
control, which correlates with a reduction of hepatic 
expression of scanvenger receptor class B type I (SR-BI), 
a well-known receptor to clear HDL cholesterol from the 
blood.25,26 Interestingly, transcriptional activation of FXR 
largely reduced plasma triglyceride levels in wild type 
mice24; FXR activation is able to suppress gene expressions 
involved in lipoprotein metabolism including sterol 
regulatory element-binding protein 1 transcription factor 
1c (SREBP-1c), phospholipid transfer protein (PLTP), 
steroyl-CoA desaturase 1 (SCD-1), the very low density 
lipoprotein receptor (VLDLR), apolipoprotein C-II, and 
apolipoprotein E. Altogether, FXR is a key molecule to 
regulate glucose and lipid homeostasis.
5. Physiological roles of FXR in the intestinal 
inflammation and anti-tumorigenesis
Previous studies have shown that FXR plays a protective 
role to control intestinal inflammation to minimize 
bacterial overgrowth.27 With cholestasis model, bile duct 
ligation compromised FXR transcriptional activity in the 
intestine. Interestingly, bile duct ligation led to bacterial 
overgrowth in the small intestine and translocation into 
other peripheral tissues.27 FXR activation by synthetic FXR 
agonist treatment attenuated bacterial overgrowth and 
reduced intestinal inflammation. Furthermore, FXR has 
been shown to regulate expression of genes involved in 
epithelial barriers and antimicrobial peptides, including 
inducible nitric oxide synthase (iNOS), occluding, and 
interleukin-18 (IL-18).27 Thus, FXR activation reduces 
bacterial overgrowth by induction of genes involved in 
epithelial barriers and antimicrobial peptides.28  
Besides intestinal inflammation, FXR has been reported 
to suppress colorectal tumorigenesis. Though bile acids 
including deoxycholic acid have been considered as 
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Fig. 4. Physiological regulation of whole body metabolism by FXR in the intestine. RXR; Retinoid X
receptor, FXR; Farnesoid X receptor.
stimulators of tumorigenesis in the colon, activation of 
FXR by synthetic FXR agonist largely suppressed intestinal 
tumorigenesis in Apc (Min/+) mice and colitis-associated 
colorectal cancer model.29 In case of FXR deficiency, Wnt 
signaling has been upregulated to promote basal 
proliferative activity in colonic epithelial cells.29 Thus, FXR 
activation would be useful in the treatment of colon 
cancer.  
6. Physiological roles of FXR in the gut to modulate 
whole body metabolism
Recent study has shown that beneficial improvements 
by vertical sleeve gastrectomy (VSG) were diminished in 
FXR-null mice.30 These results reported that VSG in wild 
type mice increased circulating bile acids and changed 
gut microbial communities. Thus, FXR signaling is an 
important molecular underpinning for the beneficial 
effects of the VSG.30 
In addition to the critical roles of FXR in VSG, a recent 
study has proposed therapeutic roles of FXR to protect 
against diet-induced obesity. By using gut-specific FXR 
synthetic agonist, named Fexaramine, intestinal specific 
FXR agonism largely increased the thermogenesis and 
mitochondrial oxidative phosphorylation in brown adipose 
tissues.31 The intestinal FXR agonism-mediated fat 
remodeling also led to increased browning of white 
adipose tissue. Thus, intestinal FXR agonism stimulated 
energy expenditure in brown and white adipose tissue, 
leading to increase whole body energy metabolism.31 The 
molecular mechanisms of how intestinal FXR agonism 
increased whole body energy metabolism remains still 
unclear. 
In contrast, another recent study has reported that 
ablation of intestine-specific FXR led to anti-obesity in 
obese animal models.32 As previously mentioned, FXR 
activation in the intestine is able to repress CYP7A1 
expression in the liver, resulting in the reduction of bile 
acid synthesis. Ablation of intestine-specific FXR largely 
increased hepatic CYP7A1 gene expression and elevated 
circulating bile acid levels.32 Given that circulating bile 
acids are able to increase local thyroid signaling in brown 
adipose tissue and basal energy expenditure,33 intestine- 
specific FXR ablation resulted in anti-obesity phenotypes 
in animal models. Furthermore, inhibition of FXR activity 
in the intestine led to remodeling of gut microbiome to 
protect against diet-induced obesity.32 Together, both 
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recent studies have suggested and demonstrated that 
regulation of intestinal FXR transcriptional activity would 
be a novel therapeutic strategy to protect against 
metabolic syndromes (Fig. 4).
CONCLUSION
Though bariatric surgery has been well known to 
improve metabolic parameters in the patients, the 
molecular mechanisms for beneficial effects still remain 
unclear. As reported, patients with bariatric surgery usually 
exhibit elevated circulating bile acid levels, FGF19, and 
Glucagon-like peptide 1 (GLP-1).34-36 Given that bile acids 
are the endogenous ligand for nuclear receptor FXR, the 
physiological roles of FXR has been widely accepted as 
a novel therapeutic target for metabolic syndromes. 
Though numerous studies have revealed various 
physiological functions of FXR in the animal models of 
metabolic diseases, the development of synthetic 
modulator to regulate FXR transcriptional activities still 
needs to be required. Since FXR has been reported as 
a critical molecule to improve beneficial metabolic 
parameter in VSG using animal model, development of 
novel synthetic modulator for FXR would be useful 
therapeutic target for metabolic diseases.
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